BR112018074299A2 - composições farmacêuticas compreendendo eteplirsen - Google Patents

composições farmacêuticas compreendendo eteplirsen

Info

Publication number
BR112018074299A2
BR112018074299A2 BR112018074299-6A BR112018074299A BR112018074299A2 BR 112018074299 A2 BR112018074299 A2 BR 112018074299A2 BR 112018074299 A BR112018074299 A BR 112018074299A BR 112018074299 A2 BR112018074299 A2 BR 112018074299A2
Authority
BR
Brazil
Prior art keywords
eteplirsen
pharmaceutical compositions
subject
administering
treating
Prior art date
Application number
BR112018074299-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Holt Thomas
Original Assignee
Sarepta Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics, Inc. filed Critical Sarepta Therapeutics, Inc.
Publication of BR112018074299A2 publication Critical patent/BR112018074299A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112018074299-6A 2016-05-24 2017-05-24 composições farmacêuticas compreendendo eteplirsen BR112018074299A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662340947P 2016-05-24 2016-05-24
US62/340,947 2016-05-24
US201662429160P 2016-12-02 2016-12-02
US62/429,160 2016-12-02
PCT/US2017/034265 WO2017213854A1 (en) 2016-05-24 2017-05-24 Pharmaceutical composition comprising eteplirsen

Publications (1)

Publication Number Publication Date
BR112018074299A2 true BR112018074299A2 (pt) 2019-03-12

Family

ID=59093599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018074299-6A BR112018074299A2 (pt) 2016-05-24 2017-05-24 composições farmacêuticas compreendendo eteplirsen

Country Status (15)

Country Link
US (1) US20190275072A1 (https=)
EP (1) EP3463390A1 (https=)
JP (1) JP2019516730A (https=)
KR (1) KR20190009343A (https=)
CN (1) CN109562123A (https=)
AU (1) AU2017278699A1 (https=)
BR (1) BR112018074299A2 (https=)
CA (1) CA3024178A1 (https=)
CO (1) CO2018013828A2 (https=)
IL (1) IL263040A (https=)
MA (1) MA45158A (https=)
MX (1) MX2018014129A (https=)
SG (1) SG11201809494VA (https=)
TW (1) TW201805002A (https=)
WO (1) WO2017213854A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
EP3806868A4 (en) * 2018-06-13 2022-06-22 Sarepta Therapeutics, Inc. EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
WO2019241385A2 (en) * 2018-06-13 2019-12-19 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystropy
JP7579147B2 (ja) * 2018-06-14 2024-11-07 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート
EP4671372A3 (en) 2024-01-29 2026-03-11 Arnatar Therapeutics, Inc Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
JP3022967B2 (ja) 1985-03-15 2000-03-21 アンチバイラルズ インコーポレイテッド 立体規則性ポリヌクレオチド結合ポリマー
EP0433345B1 (en) 1988-09-01 1994-04-20 Forskningscenter Riso Peptide synthesis method and solid support for use in the method
ATE498685T1 (de) 2004-06-28 2011-03-15 Univ Western Australia Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
MX2010004955A (es) 2007-11-15 2010-06-30 Avi Biopharma Inc Metodo de sintesis de oligomeros de morfolina.
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
RS55610B1 (sr) 2010-09-30 2017-06-30 Nippon Shinyaku Co Ltd Derivat morfolino nukleinske kiseline
ES2727481T3 (es) 2011-11-30 2019-10-16 Sarepta Therapeutics Inc Inclusión inducida de exón en atrofia muscular espinal
CN103933549A (zh) * 2013-01-17 2014-07-23 刘海俊 一种新的血管抑素滴眼剂及其制备方法
CA2906812A1 (en) * 2013-03-15 2014-09-18 Sarepta Therapeutics, Inc. Improved compositions for treating muscular dystrophy

Also Published As

Publication number Publication date
CA3024178A1 (en) 2017-12-14
CN109562123A (zh) 2019-04-02
IL263040A (en) 2018-12-31
AU2017278699A1 (en) 2018-11-15
US20190275072A1 (en) 2019-09-12
WO2017213854A1 (en) 2017-12-14
MA45158A (fr) 2019-04-10
SG11201809494VA (en) 2018-12-28
CO2018013828A2 (es) 2018-12-28
KR20190009343A (ko) 2019-01-28
EP3463390A1 (en) 2019-04-10
MX2018014129A (es) 2019-04-29
TW201805002A (zh) 2018-02-16
JP2019516730A (ja) 2019-06-20

Similar Documents

Publication Publication Date Title
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
MX385332B (es) Moduladores de ror-gamma.
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
MX394909B (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
EA201791702A1 (ru) Терапевтические средства на основе гликанов и связанные с ними способы
MX378273B (es) Compuestos activos hacia bromodominios.
SG10201902664RA (en) Combination therapy for treating cancer
WO2015117010A3 (en) Bag3 as a target for therapy of heart failure
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
EA201591925A1 (ru) Терапевтические композиции и их применение
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
EP4570314A3 (en) Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure
BR112018074299A2 (pt) composições farmacêuticas compreendendo eteplirsen
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
BR112018000217A2 (pt) sistemas de distribuição de nanopartículas aperfeiçoados
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
MY186134A (en) Curcumin-peptide conjugates and formulations thereof
NO20180002A1 (en) Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors
MX379622B (es) Compuestos espirociclicos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.

B350 Update of information on the portal [chapter 15.35 patent gazette]